HRS-7535 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
HRS-7535 is Hengrui's daily GLP-1 pill. Two large final-stage studies in China worked, with about 11 percent weight loss at 50 weeks. It has been filed in China, and Kailera is running a global mid-stage study.
Evidence grade for HRS-7535: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 235 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 235
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 235 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
HRS-7535 is a daily GLP-1 pill from Hengrui in China. Kailera has the rights outside China. It has been filed for approval in China. It is not approved anywhere yet.
What people take it for
- GLP-1 weight loss in a pill.
- Lower blood sugar in type 2 diabetes.
What studies in people showed
Two large final-stage studies both worked. In the obesity study, people on 180 mg lost 11.1 percent of their weight at 50 weeks. People on a dummy pill lost 2.4 percent. In the diabetes study, the three-month blood sugar average fell 1.5 to 1.7 points. An earlier study had 235 adults in China. The top dose took off about 9 percent in 26 weeks, against about 2.5 percent on the dummy. In the very first study, healthy volunteers lost 4.38 kg in 28 days.
What people report
Reports, not study results
The good
- In the studies on this page, people lost about a tenth of their weight over a year on a daily pill.
The bad
- Nausea, vomiting and other stomach upsets were the most common complaints in the studies on this page. They were mostly mild.
Where these come from: Both lines are from the studies and the company release on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Two big studies that worked is a solid start. It is not approved outside China yet. If you want a GLP-1 pill, ask your doctor about the approved ones.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals HRS-7535 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight235 people · 2 studies
- Blood sugar and insulinno headcount stated · 1 study
34 of the 36 indexed goals have no study of any kind behind HRS-7535
No study in people, animals or cells on this page reports a result for these. That does not prove HRS-7535 does nothing for them. It does mean anything you have heard about HRS-7535 and one of these did not come from a study cited here.
Show full evidence
What is HRS-7535?
HRS-7535 is Hengrui's daily GLP-1 pill. Two large final-stage studies in China worked, with about 11 percent weight loss at 50 weeks. It has been filed in China, and Kailera is running a global mid-stage study.
HRS-7535 is a GLP-1 drug in pill form. In July 2026, Hengrui and Kailera reported two final-stage studies. In the obesity study, HARBOR-1, people on 180 mg lost 9.8 to 10.9 percent of their weight at 44 weeks, and 11.1 percent at week 50. People on a dummy pill lost 2.4 percent. In the diabetes study, OUTSTAND-2, HbA1c, a three-month blood sugar average, fell 1.5 to 1.7 points. In an earlier mid-stage study, 235 adults in China lost 9.36 percent on the top dose in 26 weeks, against 2.50 percent on a dummy pill. It has been filed for approval in China. That could make it the second pill of its kind approved anywhere, after orforglipron.
How does HRS-7535 work?
It is a small molecule, taken as a pill, that turns on the GLP-1 signal.
The evidence, in charts
Fig. 1a · how many people
235people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Nature Communications 2026 | 235 | 100% |
The whole total is one study of 235. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 3 sources here are studies in people.
- Study in people · done in people3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2024 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 592.1 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for HRS-7535, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026Positive topline data from two Phase 3 trials of oral GLP-1 HRS-7535 / KAI-7535
Two large final-stage trials both came out positive. Over about a year, people taking the daily pill lost roughly 11% of their body weight, against a little over 2% on a dummy pill. In the separate diabetes trial, average blood sugar over three months fell by 1.5 to 1.7 percentage points. Both results arrived as a company announcement. Neither trial has been published in full, so the safety detail is not yet public.
About 11% weight loss at 50 weeks; HbA1c down 1.5% to 1.7%.
- Study in people2026HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
The pill worked in its first real test in people with obesity. 235 adults in China took one of four doses or a dummy pill. After half a year the top dose took off about 9 percent of body weight, against about 2.5 percent on the dummy. Nausea and other stomach upsets were the most common complaint and were mostly mild. Everyone in the study was Chinese, and half a year is a short look.
235 adults with BMI 28 to 40 randomised across four doses and placebo. At week 26 mean weight change was -9.36% on 180 mg against -2.50% on placebo (placebo-adjusted -6.87%); gastrointestinal events were the most common and were mostly mild to moderate.
- Study in people2024Safety, pharmacokinetics and pharmacodynamics of HRS-7535 in healthy participants: a phase 1 randomized, double-blind, placebo-controlled trial
This was the first time the drug was given to people, and it was built to check for harm rather than benefit. Healthy volunteers took single doses, then rising daily doses for 28 days, some with food and some without. It showed the drug lasts long enough in the body for one pill a day. Nausea and vomiting were the commonest complaints. Volunteers lost 4.38 kg over 28 days against 0.8 kg on a dummy pill, but healthy volunteers are not who the drug is for.
First-in-human single- and multiple-ascending-dose and food-effect study that established the once-daily oral dosing profile.
Common questions
Has HRS-7535 been tested in people?
Yes. 235 people given it across 2 completed trials cited here, 0 of which found nothing. HRS-7535 is Hengrui's daily GLP-1 pill. Two large final-stage studies in China worked, with about 11 percent weight loss at 50 weeks. It has been filed in China, and Kailera is running a global mid-stage study.
What is the HRS-7535 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 235 people given it
Is HRS-7535 FDA-approved?
Investigational in the US; the maker has applied for approval in China
Will HRS-7535 be sold in the US?
Not soon. Kailera holds the rights outside China and has only started a global mid-stage study. US approval would need its own large final-stage studies.
Latest reading on HRS-7535
Blog posts about HRS-7535, newest first.